This report was first published by Endpoints News. To see the original version, click here
Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the “don’t eat me” signal from the cancer field into the cardiovascular realm.
The Palo Alto-based biotech had shipped a CD47-targeting immunomodulating protein drug into a Phase 2a study in Australia. The trial of BRB-002 began dosing patients with atherosclerosis in June 2025. That work appears to have hit a snag, sending Bitterroot back to the drawing board.
您已阅读21%（608字），剩余79%（2221字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。